SARS-CoV-2 Protein Subunit Recombinant Vaccine

Developed for: COVID-19
Investigated by: PT Bio Farma · Andalas University · Faculty of Medicine, Diponegoro University, Semarang · Faculty of Medicine, University of Indonesia · Center for Child Health Universitas Gadjah Mada (CCH-PRO UGM · Dr Cipto Mangunkusumo General Hospital
+3 more
· Faculty of Medicine, Universitas Hassanudin, Makassar · Indonesia University · National Institute of Health Research and Development, Ministry of Health Republic of Indonesia

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT05228613	Feb → Aug 2022	COVID-19	PT Bio Farma	Completed	No outcome recorded
Phase 1	NCT05067894	Dec 2021 → Apr 2022	COVID-19	PT Bio Farma	Completed	No outcome recorded
Phase 2/31 trial
Phase 2/3	NCT05313035	Apr → Jul 2022	COVID-19	PT Bio Farma	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT05546502	Oct 2022 → Dec 2023	vaccinia	PT Bio Farma	Completed	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	SARS-CoV-2 Protein Subunit Recombinant Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05067894 ↗ 3 NCT05313035 ↗ NCT05546502 ↗ NCT05228613 ↗
Modality	Vaccine	“SARS-CoV-2 Protein Subunit Recombinant Vaccine” NCT05067894 ↗